KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

DANOL 200 MG CAPSULES

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

200 MG

 

GENERIC NAME:

DANAZOL

 

MANUFACTURER:

STERLING

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

X

 

INDICATIONS:

Angioedema

Endometriosis

Fibrocystic breast disease

 

SIDE EFFECTS:

Amenorrhea

breakthrough bleeding

decrease in breast size

irregular menstrual periods

spotting

weight gain

Peripheral edema

rhabdomyolysis

virilization

Adenoma, hepatocellular

bladder telangiectasia

bleeding gums

carpal tunnel syndrome

cataracts

cholestatic jaundice

discharge from nipple

eosinophilia

hepatic dysfunction

intracranial hypertension, benign

leukocytosis

pancreatitis, acute

peliosis hepatis

polyneuritis, acute idiopathic

skin rash

Stevens-Johnson syndrome

thrombocytopenia

thromboembolism or thrombotic and thrombophlebitic events including stroke

sagittal sinus thrombosis

Virilization

Abnormalities in semen viscosity and volume, and in sperm count and motility

testicular atrophy

Hypoestrogenemia

Photosensitivity

Vaginitis

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

Cardiac function impairment

Epilepsy

Migraine headaches

Renal function impairment

Diabetes mellitus

 

ADULT DOSE:

Endometriosis-Moderate to severe: Oral, 400 mg two times a day (beginning Day 1 of menstruation, if possible) for at least three to six months, and may be continued for nine months if necessary. Mild: Oral, 100 to 200 mg two times a day (beginning Day 1 of menstruation, if possible) for at least three to six months, and may be continued for nine months if necessary. Note: If symptoms recur after discontinuation of therapy, therapy may be reinstituted. Fibrocystic breast disease-Oral, 50 to 200 mg two times a day (beginning Day 1 of menstruation, if possible) for six months or until the symptoms completely disappear, whichever comes first. Note: If symptoms recur within one year of discontinuation of therapy, therapy may be reinstituted. Hereditary angioedema, prophylaxis of -Oral, initially 200 mg two or three times a day until the desired initial response is obtained; then the maintenance dosage is determined by decreasing the initial dosage by 50% or less at intervals of one to three months or longer, depending on the frequency of attacks prior to treatment. Note: Daily dosage may be increased by up to 200 mg if the condition is not controlled at lower doses. [Primary menorrhagia]-Oral, 200 to 400 mg a day, in divided doses (beginning Day 1 of menstruation, if possible), for up to six months. Note: If no improvement is seen after two or three cycles, therapy should be discontinued and the cause of the excess bleeding reassessed.

 

MAXIMUM ADULT DOSE:

800 mg per day.

 

PEDIATRIC DOSE:

Dosage has not been established.  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT